Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01521663 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)
A Phase 2 study, sponsored by Impax Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT01521663 is a Phase 2 study that has completed, run by Impax Laboratories. The registered enrollment target is 159 participants.
The verdict
NCT01521663, a Phase 2 study, has completed, sponsored by Impax Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether IPX159 is safe and effective in treating symptoms of RLS in subjects with Restless Legs Syndrome.
Interventions
- DRUG Placebo
- DRUG IPX159
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01521663
The ClinicalTrials.gov registry entry for NCT01521663 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Impax Laboratories, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01521663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01521663 about?
NCT01521663 is a clinical study titled "Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)". The purpose of this study is to determine whether IPX159 is safe and effective in treating symptoms of RLS in subjects with Restless Legs Syndrome.
What is the current status of trial NCT01521663?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2011-11. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01521663?
The interventions under investigation include: Placebo (DRUG), IPX159 (DRUG).
Who is sponsoring clinical trial NCT01521663?
This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.